Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy

Current cancer immunotherapy has limited response rates in a large variety of solid tumors partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor microenvironment (ITM). A number of clinical cancer treatment modalities, including radiotherapy, chemotherapy, photother...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jing, Wang, Wei-qi, Pei, Qing, Lord, Megan S., Yu, Hai-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470797/
https://www.ncbi.nlm.nih.gov/pubmed/32317755
http://dx.doi.org/10.1038/s41401-020-0400-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470797/
https://www.ncbi.nlm.nih.gov/pubmed/32317755
http://dx.doi.org/10.1038/s41401-020-0400-z

Ejemplares similares